Most accountants never bought Xero. Doctors are good at Dr stuff and few are good investors. I am not sure there should be an expected correlation between Dr purchases and the success of the company. The small illiquid nature of the stock means it moves sharply in either direction. It is just as likely to move up in a hurry at any stage as it did down. Instead of thinking of it as a tough watch I have been grateful for the opportunity to top up while the market figures this one out.
The latest update indicting an ability to detect ischaemic stroke at very early stages (earlier than some non contrast CT’s can pick up) was huge IMO.
DYOR and Not advice.
EMvision Research Notes, page-2534
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.00 |
Change
0.020(1.01%) |
Mkt cap ! $170.4M | |||
| Open | High | Low | Value | Volume |
| $1.98 | $2.00 | $1.98 | $37.48K | 18.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 255 | $1.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.00 | 4046 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| EMV (ASX) Chart |